TARGINIQ Drug Patent Profile
✉ Email this page to a colleague
When do Targiniq patents expire, and when can generic versions of Targiniq launch?
Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries.
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Targiniq
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 30, 2025. This may change due to patent challenges or generic licensing.
There have been twenty-eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TARGINIQ?
- What are the global sales for TARGINIQ?
- What is Average Wholesale Price for TARGINIQ?
Summary for TARGINIQ
| International Patents: | 151 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 7 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TARGINIQ |
| What excipients (inactive ingredients) are in TARGINIQ? | TARGINIQ excipients list |
| DailyMed Link: | TARGINIQ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TARGINIQ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for TARGINIQ
TARGINIQ is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TARGINIQ is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TARGINIQ
Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxycodone compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARGINIQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TARGINIQ
See the table below for patents covering TARGINIQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 2425821 | ⤷ Sign Up | |
| China | 102887903 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | ⤷ Sign Up |
| Denmark | 2305683 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARGINIQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | C300619 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530 |
| 1685839 | CA 2013 00052 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530 |
| 1685839 | 122013000082 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
